Navigation Links
NeurogesX in Medical News

NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors

...no opportune time to resign, I feel confident that neurogesx is well positioned following the recent E.U. appro... of these accomplishments I am comfortable leaving neurogesx while I focus more of my energies on Alba Therapeutics." Tony DiTonno, neurogesx CEO commented, "We would like to thank Bruce for a...

NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)

... commitments, to support Qutenza in the EU market. neurogesx will receive EUR 30 million (approximately $42 mil...the Distribution, Marketing and License Agreement, neurogesx will receive two upfront payments from Astellas, E...ent and commercialization option of NGX-1998. neurogesx is eligible for additional sales-based milestone p...

NeurogesX Reports Fourth Quarter and Year-End 2008 Results

...n update on recent developments. During 2008, neurogesx continued to make significant progress on the regu...cacy in a shorter application time versus Qutenza. neurogesx is currently evaluating the timing to initiate Phase 2 development of NGX-1998. neurogesx continues to pursue business development opportuni...

NeurogesX to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference

...f the presentation will be available for 15 days. About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company focused on developing and c...consult NeurogesX' filings with the Securities and Exchange Commission. neurogesx Stephen Ghiglieri (650) 358-3310 sghiglieri@neurogesx.com The Ruth G...

NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results

... Officer, commented, "2007 was a positive year for neurogesx in terms of moving our product candidates forward ...ulatory and Commercialization Plans for NGX-4010 neurogesx submitted an MAA for NGX-4010, which was accepted ...sful Phase 3 studies, one each in PHN and HIV-DSP. neurogesx is evaluating strategies regarding its MAA that ma...

NeurogesX to Present at Susquehanna Financial Group's 2nd Annual SIGnificant Options in Healthcare Conference

...e available for 15 days. About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company fo... to, statements concerning future presentations by neurogesx and the expected benefits of NeurogesX' potential ...s with the Securities and Exchange Commission. neurogesx The Ruth Group Anthony DiTonno ...

NeurogesX to Present at RBC Capital Markets 2007 Healthcare Conference

...f the presentation will be available for 15 days. About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company focused on developing novel...onsult NeurogesX' filings with the Securities and Exchange Commission. neurogesx The Ruth Group Stephen Ghiglieri In...

NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007

... web site beginning November 14, 2007 at approximately 6:00 p.m. ET. The replay will remain available until December 14, 2007. About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chr...

Pharsight Achieves $7.3 Million in Quarterly Revenue

...3 different projects for the business unit, including projects with 3 customers new to Pharsight: Lupin Pharmaceuticals, Seattle Genetics and neurogesx -- Expanded the RAS team with the addition of four scientific specialists. -- Continued to expand the internship program with the first intern hire ...
NeurogesX in Medical Technology

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

...teful to our clinical investigators and the entire neurogesx team for working together to quickly complete this...rocedure." About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company f...mbination with other medicinal products for pain. neurogesx submitted a new drug application (NDA) for PHN to ...

NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia

...pioid analgesics. About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company f...ombination with other medicinal products for pain. neurogesx submitted a new drug application (NDA) for Qutenza.... NGX-1998 has completed three Phase 1 studies and neurogesx is currently evaluating the timing of entering Pha...

NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology

...to the current treatment options for PHN." About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company focused on developing and ...rposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). neurogesx disclaims any intent or obligation to update these forward-looking statemen...

NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation

...exploratory investigational new drug application. About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company focused on developing and c...onsult NeurogesX' filings with the Securities and Exchange Commission. neurogesx The Ruth Group Stephen Ghiglieri ...

NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology

...fects being transient application site reactions. About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company focused on developing and c...consult NeurogesX' filings with the Securities and Exchange Commission. neurogesx The Ruth Group Stephen Ghiglieri I...

NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP

...ulatory and Commercialization Plans for NGX-4010 neurogesx submitted an MAA, which was accepted by the EMEA u...ath forward for attaining approval for HIV- DSP. neurogesx has retained exclusive worldwide commercialization...s or Europe for HIV-DSP. About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company fo...

NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy

...eases our confidence that we can meet this goal." neurogesx has successfully completed two Phase 3 studies in ...d fast track designation from the FDA for HIV-DSP. neurogesx believes that it is on track to file for marketing...ain in the feet and hands. About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company fo...

NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy

...eases our confidence that we can meet this goal." neurogesx has successfully completed two Phase 3 studies in ...d fast track designation from the FDA for HIV-DSP. neurogesx believes that it is on track to file for marketing...ain in the feet and hands. About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company fo...

NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia

...gulatory and Commercialization Plans for NGX-4010 neurogesx remains on track to complete the filing of a marke... centers and physicians who treat PHN and HIV-DSP. neurogesx intends to enter into commercial partnerships for ...tes or Europe for HIV-DSP. About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company fo...

NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)

...ity of the skin that can persist for many years. neurogesx plans to complete a confirmatory Phase 3 trial in ...convulsants, anti-depressants and opioids. About neurogesx neurogesx is a biopharmaceutical company focused on developi...
NeurogesX in Biological Technology

NeurogesX Reports Second Quarter 2009 Results

...dicinal products for pain. Following the approval, neurogesx finalized an exclusive agreement with Astellas Pha...bmission. With the PDUFA date approaching, neurogesx continued with certain U.S. pre-commercialization .... launch of Qutenza in the first half of 2010. The neurogesx team has performed exceptionally, both in respondi...

NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application

...er 7, 2009. About NeurogesX, Inc. neurogesx (NASDAQ: NGSX ) is a biopharmaceutical company f...Astellas Pharma Europe, Ltd. In the United States, neurogesx submitted a new drug application (NDA) for PHN to .... NGX-1998 has completed three Phase 1 studies and neurogesx is currently evaluating the design and timing of f...

NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results

...er 7, 2009. About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company f...iary of Astellas Pharma Inc. In the United States, neurogesx submitted a new drug application (NDA) for PHN to .... NGX-1998 has completed three Phase 1 studies and neurogesx is currently evaluating the timing of entering Pha...

NeurogesX Added to Russell 3000 Index

... NeurogesX, commented, "We welcome the addition of neurogesx to the Russell 3000 index, which is well timed wit...tment strategies. About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company f...ies in eastern Europe, the middle east and Africa. neurogesx submitted a new drug application (NDA) for Qutenza...

NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)

...ed on the expected short-term nature of the study, neurogesx could potentially complete enrollment, analyze the... half of 2010." About NeurogesX, Inc. neurogesx (NASDAQ: NGSX ) is a biopharmaceutical company f...mbination with other medicinal products for pain. neurogesx submitted a new drug application (NDA) for Qutenza...

NeurogesX to Present at Needham Life Sciences Conference

...hived for 90 days. About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company f...mbination with other medicinal products for pain. neurogesx submitted a new drug application (NDA) for Qutenza.... NGX-1998 has completed three Phase 1 studies and neurogesx is currently evaluating the timing of entering Pha...

NeurogesX Receives European Commission Approval for Qutenza(TM)

...a in patients with PDN have not been studied. neurogesx anticipates that Qutenza will be marketed in the E...culmination of years of development efforts by the neurogesx team and represents a validation both of our peopl...emic side effects. About NeurogesX, Inc. neurogesx (NASDAQ: NGSX ) is a biopharmaceutical company f...

NeurogesX Reports First Quarter 2009 Results

...velopments. During the first quarter of 2009, neurogesx continued to focus on seeking regulatory approvals...ial marketing authorization and commercialization, neurogesx has continued active discussions with potential Eu...ion." Development Update Currently, neurogesx is primarily focused on completing the development...

NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results

...h June 7, 2009. About NeurogesX, Inc. neurogesx (Nasdaq: NGSX ) is a biopharmaceutical company f...iated with peripheral neuropathic pain conditions. neurogesx submitted a new drug application (NDA) for Qutenza...mbination with other medicinal products for pain. neurogesx is currently awaiting the European Commission's de...

NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting

...at were mostly mild to moderate in intensity. neurogesx submitted a new drug application (NDA) for Qutenza...mbination with other medicinal products for pain. neurogesx is currently awaiting the European Commission's de...e daily doses. About NeurogesX, Inc. neurogesx (NASDAQ: NGSX ) is a biopharmaceutical company f...
Other Tags
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... CAGR of 7.2% to reach $5,756.0 million by ... the microscopy market. The electron microscopes product segment ... the forecast period. , Rising focus on nanotechnology, ... growth of the microscopy market. , Get Full ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
(Date:12/25/2014)... 2014 “Every three months the trends for ... sweetheart evening dress will be one of the hottest styles ... Yunx.co.uk says. Today, the company releases 26 A-line sweetheart evening ... 80% off. , “We are trying our best to ... our latest designs. Along with affordable prices, we provide discounted ...
(Date:12/25/2014)... December 26, 2014 Recently, Dylan Queen, ... has excitedly released its collection of discounted prom dresses, ... Percy, a senior spokesman of the company, the promotion ... this promotion is to expand the UK market. , ... several different colors, lengths, and styles: A-line strapless, empire ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
(Date:12/19/2014)... 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... in July 2012, Apple introduced the fingerprint reading ... the only device of Apple incorporating such a ...
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
Other Contents